ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2016
Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 113 citations in OpenAlex.
- Burden and Challenges in the Diagnosis and Treatment of Histoplasmosis Among Persons With Advanced HIV Disease in Uganda, 2025.Open forum infectious diseases · 2026Article
- A Drug-Drug Interaction of Ainuovirine with Fluconazole in Healthy Adults and Dose Optimization Informed by Pharmacokinetics Modelling.Drug design, development and therapy · 2026Article
- Does the use of topical azoles have an impact on antifungal resistance?The Journal of antimicrobial chemotherapy · 2025Article
- Disseminated liver histoplasmosis in an immunocompetent individual cured by liver transplantation and voriconazole from China: A case report.World journal of gastroenterology · 2025Article
- Access to diagnostic testing for invasive fungal diseases and other opportunistic infections in Mexican health care centers caring for patients living with HIV.BMC health services research · 2025Article
- Three new asexualMycoKeys · 2025Article
- Antifungal activity of ETD151 against azole-susceptible and -resistantCurrent research in microbial sciences · 2025Article
- Febrile Pancytopenia and Hemophagocytosis From Disseminated Histoplasmosis in HIV/AIDS Patients: Two Cases and a Review of Combined Antifungal and Steroid Therapy.Case reports in infectious diseases · 2025Article
- An unusual case of a dry cough.Breathe (Sheffield, England) · 2024Article
- Genotypic diversity, virulence, and molecular genetic tools inMicrobiology and molecular biology reviews : MMBR · 2024Review
- Fungal infections in Sudan: An underestimated health problem.PLoS neglected tropical diseases · 2023Article
- Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health.ACS bio & med chem Au · 2023Review
- CT imaging of HIV-associated pulmonary disorders in COVID-19 pandemic.Clinical imaging · 2023Review
- Recognition of fungal priority pathogens: What next?PLoS neglected tropical diseases · 2023Article
- TheiaEuk: a species-agnostic bioinformatics workflow for fungal genomic characterization.Frontiers in public health · 2023Article
- Comprehensive genome-scale metabolic model of the human pathogenFrontiers in bioinformatics · 2023Article
- Hepatic Histoplasmosis: An Update.Journal of clinical and translational hepatology · 2022Review
- Cryptococcal andOpen forum infectious diseases · 2022Article
- Phytochemicals and Biological Activities ofPlants (Basel, Switzerland) · 2021Review
- Updated estimated incidence and prevalence of serious fungal infections in Trinidad and Tobago.IJID regions · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deaths from AIDS (1 500 000 in 2013) have been falling more slowly than anticipated with improved access to antiretroviral therapy. Opportunistic infections account for most AIDS-related mortality, with a median age of death in the mid-30s. About 360 000 (24%) of AIDS deaths are attributed to tuberculosis. Fungal infections deaths in AIDS were estimated at more than 700 000 deaths (47%) annually. Rapid diagnostic tools and antifungal agents are available for these diseases and would likely have a major impact in reducing deaths. Scenarios for reduction of avoidable deaths were constructed based on published outcomes of the real-life impact of diagnostics and generic antifungal drugs to 2020. Annual deaths could fall for cryptococcal disease by 70 000, Pneumocystis pneumonia by 162 500, disseminated histoplasmosis by 48 000 and chronic pulmonary aspergillosis by 33 500, with approximately 60% coverage of diagnostics and antifungal agents; a total of >1 000 000 lives saved over 5 years. If factored in with the 90-90-90 campaign rollout and its effect, AIDS deaths could fall to 426 000 annually by 2020, with further reductions possible with increased coverage. Action could and should be taken by donors, national and international public health agencies, NGOs and governments to achieve the UNAIDS mortality reduction target, by scaling up capability to detect and treat fungal disease in AIDS.This article is part of the themed issue 'Tackling emerging fungal threats to animal health, food security and ecosystem resilience'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.